Department of Experimental Rheumatology, Institute of Rheumatology, Prague, Czech Republic.
Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Rheumatology (Oxford). 2021 Apr 6;60(4):1823-1831. doi: 10.1093/rheumatology/keaa518.
Individuals carrying antibodies against citrullinated proteins (ACPA) are at high risk of developing RA. EULAR provided a clinical definition of individuals with arthralgia suspicious for progression to RA (clinically suspect arthralgia, CSA). The alteration of monocyte subpopulations in patients with established RA has been previously described. We analysed peripheral blood monocyte subpopulations in individuals with arthralgia at risk of RA.
We included 70 at-risk individuals, defined as having arthralgia without arthritis and being either ACPA+ or meeting the clinical CSA definition, 23 patients with early RA (ERA) and 19 healthy controls (HCs). Monocytes classified as classical (CD14++CD16-), intermediate (CD14++CD16+/++) and nonclassical (CD14-/+CD16++) were analysed by flow cytometry.
Of the 70 at-risk individuals, 46 were ACPA+ and 45 met the CSA definition. The at-risk individuals and, especially, ERA patients had a lower percentage of classical monocytes and a higher percentage of nonclassical monocytes than the HCs. ACPA positivity had no effect on the difference in the distribution of the monocyte subsets between at-risk individuals and ERA patients, but a difference was determined in those reaching the ERA phase. However, when compared with HCs, the shift of monocyte subsets was more significant in ACPA+ than in ACPA- individuals with arthralgia. This trend was observed in individuals who did not meet the CSA definition. This finding was, however, determined by a selection bias, as these individuals were solely ACPA+.
The shift from classical to nonclassical monocyte subpopulations was observed already in individuals at risk of developing RA.
携带抗瓜氨酸化蛋白抗体(ACPA)的个体患 RA 的风险很高。EULAR 提供了一个临床定义,用于定义有进展为 RA 风险的关节痛患者(临床可疑性关节痛,CSA)。已有研究描述了已确诊 RA 患者单核细胞亚群的改变。我们分析了有进展为 RA 风险的关节痛患者外周血单核细胞亚群。
我们纳入了 70 名高危个体,定义为有不伴关节炎的关节痛且为 ACPA+或符合临床 CSA 定义,23 名早期 RA(ERA)患者和 19 名健康对照(HCs)。通过流式细胞术分析经典(CD14++CD16-)、中间(CD14++CD16+/++)和非经典(CD14-/+CD16++)单核细胞亚群。
在 70 名高危个体中,46 名为 ACPA+,45 名符合 CSA 定义。高危个体,特别是 ERA 患者,经典单核细胞比例较低,非经典单核细胞比例较高,而 HCs 则相反。ACPA 阳性对高危个体和 ERA 患者之间单核细胞亚群分布的差异没有影响,但在进入 ERA 阶段时会出现差异。然而,与 HCs 相比,ACPA+关节痛患者的单核细胞亚群分布变化更为显著,而 ACPA-患者的变化则不显著。这种趋势在不符合 CSA 定义的个体中更为明显。这一发现是由于选择偏倚造成的,因为这些个体仅为 ACPA+。
在有进展为 RA 风险的个体中已经观察到从经典单核细胞向非经典单核细胞亚群的转变。